One of the premier peer-reviewed clinical journals in general and internal medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 125,000. Mayo Clinic Proceedings is published by Elsevier and sponsored by Mayo Clinic and the Mayo Foundation for Medical Education and Research. The mission of Mayo Clinic Proceedings is to promote the best interest of patients by advancing the knowledge and professionalism of the physician community. Since 2009 the Journal has offered CME credit for specific articles from both the Mayo Clinic for Concise Review for Clinicians and specially commissioned Symposia articles (comprehensive coverage on one topic).  

Participation in this activity consists of reviewing articles and responding to a short online test. It is estimated that this activity will take approximately one hour per article.  There is no charge for participating in this Journal CME activity.

NOTE: You must select AMA PRA Category 1 Credit^TM in your profile's credit eligiblility field in order for the sytem to recognize that you want CME credit. The system will only issue credit for the credit types that match your profile.

To receive CME credit, please do the following:

• Click Take Course
• Complete quiz and evaluation (There is a required 80% pass rate in order to earn credit, with 1 retake allowed.)
• Print your Record of Attendance

Questions?  cme@mayo.edu

ACCREDITATION:

Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Mayo Clinic College of Medicine designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE SUMMARY:
Planning Committee:
William Lanier, M.D., Thomas Beckman, M.D., Christopher M. Wittich, M.D., Terry Jopke, Nicki Smith

Authors:
Ayushman Sharma MD, Jeffrey R. Janus MD, Grant S. Hamilton, MD FACS

DISCLOSURES:  No financial disclosures. 

References to off-label and/or investigational  usage(s) of pharmaceuticals or instruments: 

Alloderm-LifeCell
Integra- Integra LifeSciences

Product(s)/Device(s)
Alloderm and other products from human skin tissue are regarded as minimally processed and not significantly changed in structure from the natural material; FDA classifies it as banked human tissue and therefore, does not require FDA approval.

Integra® Dermal Regeneration Template (Integra LifeSciences) is a bovine, collagen/glycosaminoglycan dermal replacement covered by a silicone temporary epidermal substitute. It is FDA-approved for use in postexcisional treatment of life-threatening full-thickness or deep partial-thickness thermal injury where sufficient autograft is not available at the time of excision or not desirable because of the physiologic condition of the patient. Integra™ Matrix Wound Dressing and Integra™ meshed Bilayer Wound Matrix are substantially equivalent skin substitutes that are FDA-510(k) approved for other indications.